Ignite Creation Date:
2024-05-06 @ 3:20 AM
Last Modification Date:
2024-10-26 @ 11:31 AM
Study NCT ID:
NCT02260557
Status:
COMPLETED
Last Update Posted:
2016-05-10
First Post:
2014-10-06
Brief Title:
Effects of Selexipag in Adults With Raynauds Phenomenon Secondary to Systemic Sclerosis
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
A Multi-center Double-blind Randomized Placebo-controlled Parallel Group Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynauds Phenomenon Secondary to Systemic Sclerosis
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynauds Phenomenon RP secondary to Systemic Sclerosis SSc
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None